A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Phase I: dose limiting toxicity (DLT)
A DLT is defined as an adverse event or abnormal laboratory value as defined in the protocol that is assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment with AEB071and MEK162.
Up to 28 days of treatment with AEB071 and MEK162
European Union: European Medicines Agency
|Dana Farber Cancer Institute Dept. Onc||Boston, Massachusetts 02115|
|Memorial Sloan Kettering Cancer Center Dept of Onc..||New York, New York 10021|